Dr. Bauml on CAR T-Cell Therapy in Head and Neck Cancer

Joshua Bauml, MD
Published: Wednesday, Jul 26, 2017



Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses chimeric antigen receptor (CAR) T-cell therapy in head and neck cancer.

There could be a place for CAR T-cell therapy in head and neck cancer, says Bauml, but there are limitations.

SELECTED
LANGUAGE


Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses chimeric antigen receptor (CAR) T-cell therapy in head and neck cancer.

There could be a place for CAR T-cell therapy in head and neck cancer, says Bauml, but there are limitations.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x